CD274 and cancer: Although the application of immunotherapy has shown considerable value in the diagnosis, treatment, and prediction of various cancers, the response rates of patients with positive PD-L1 pathology to immunotherapy is only 10–30% (Fehrenbacher et al., 2016; Eggermont et al., 2018).